Interleukin Inhibitors Market by Product and Geography - Global Forecast and Analysis 2019-2023
Global Interleukin Inhibitors Market: About this market
Technavio’s Interleukin inhibitors market analysis considers sales from Interleukin-23 inhibitors, Interleukin-17 inhibitors, Interleukin-6 inhibitors, and other Interleukin inhibitors. Our analysis also considers the sales of Interleukin inhibitors in Asia, Europe, North America, and ROW. In 2018, the Interleukin-23 inhibitors segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high prevalence of psoriasis and improved R&D on Interleukin-23 inhibitors will help in the growth of Interleukin-23 inhibitors segment and maintain its market position. Also, our global Interleukin inhibitors market report looks at factors such as high target affinity and specificity of Interleukin inhibitors, recent approvals and robust pipeline, and presence of reimbursement and patient assistance program. However, availability of substitutes, product withdrawals and failure of clinical trials, and adverse side effects and high cost of Interleukin inhibitors may hamper the growth of the Interleukin inhibitors industry over the forecast period.
Global Interleukin Inhibitors Market: Overview
High target affinity and specificity of Interleukin inhibitors
Interleukin inhibitors are target specific and work directly in Interleukin receptors. These drugs are highly effective in the treatment of autoimmune diseases such as psoriasis, rheumatoid arthritis, and Crohn’s disease. Higher patient adherence to these drugs because of their higher affinity and specificity. The advances in the R&D Interleukin drugs and clinical trials for late-stage molecules is expected to lead the expansion of the global Interleukin inhibitors market at a CAGR of almost 13% during the forecast period.
Increasing awareness about autoimmune diseases
The major focus of the awareness programs is to educate people about the symptoms of various arthritis indications, cause of the diseases, risk factors that cause inflammation, availability of various treatments and preventive measures that can be taken to control the disease. These awareness campaigns are expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global Interleukin inhibitors market during the forecast period 2019-2023, click here.
With the presence of several major players, the global Interleukin inhibitors market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Interleukin inhibitors manufacturers, that include Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Novartis AG, Regeneron Pharmaceuticals Inc.
Also, the Interleukin inhibitors analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook